{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T19:07:38Z","timestamp":1785265658332,"version":"3.55.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,24]],"date-time":"2020-06-24T00:00:00Z","timestamp":1592956800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,24]],"date-time":"2020-06-24T00:00:00Z","timestamp":1592956800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>This study was performed to evaluate clinical characteristics of branch retinal vein occlusion (BRVO) patients with increased retinal haemorrhage during macular oedema (MO) treatment. Patients were divided into increased and non-increased retinal haemorrhage groups. The former group was sub-divided based on the degree of increase:\u2009&lt;\u200950% or\u2009\u2265\u200950%. Baseline characteristics, clinical data, and best vision achieved before and after increased retinal haemorrhage were assessed. Sixty-eight eyes of 68 patients were included. Forty-six eyes were non-increased, 11 eyes experienced\u2009&lt;\u200950% increase in retinal haemorrhage, and 11 eyes had\u2009\u2265\u200950% increase. Ischaemic BRVO was related to increased haemorrhage based on the multivariate analysis. The\u2009\u2265\u200950% increase group exhibited higher baseline central subfield macular thickness (CSMT), poorer baseline best corrected visual acuity (BCVA), and longer mean periods between the final intravitreal injections and the time increased retinal haemorrhages were observed, compared to the\u2009&lt;\u200950% group. The best vision achieved before and after increased haemorrhage was significantly worse in the\u2009\u2265\u200950% group. In conclusion, the ischaemic type of BRVO is related to increased retinal haemorrhage during MO treatment, and a\u2009\u2265\u200950% increase in haemorrhages is associated with higher CSMT and poorer BCVA at baseline, with poor visual gain.<\/jats:p>","DOI":"10.1038\/s41598-020-67395-7","type":"journal-article","created":{"date-parts":[[2020,6,24]],"date-time":"2020-06-24T10:02:52Z","timestamp":1592992972000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Clinical characteristics of branch retinal vein occlusion with increased retinal haemorrhage during treatment for macular oedema"],"prefix":"10.1038","volume":"10","author":[{"given":"You Hyun","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu Cheol","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,24]]},"reference":[{"key":"67395_CR1","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/j.ophtha.2010.01.058","volume":"117","author":"SL Rogers","year":"2010","unstructured":"Rogers, S. L. et al. Natural history of branch retinal vein occlusion: An evidence-based systematic review. Ophthalmology 117, 1094-1101.e1095 (2010).","journal-title":"Ophthalmology"},{"key":"67395_CR2","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1097\/IAE.0b013e3182870c15","volume":"33","author":"A Jaulim","year":"2013","unstructured":"Jaulim, A., Ahmed, B., Khanam, T. & Chatziralli, I. P. Branch retinal vein occlusion: Epidemiology, pathogenesis, risk factors, clinical features, diagnosis, and complications. An update of the literature. Retina 33, 901\u2013910 (2013).","journal-title":"Retina"},{"key":"67395_CR3","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1111\/j.1442-9071.1980.tb00340.x","volume":"8","author":"DV Greer","year":"1980","unstructured":"Greer, D. V., Constable, I. J. & Cooper, R. L. Macular oedema and retinal branch vein occlusion. Aust. J. Ophthalmol. 8, 207\u2013209 (1980).","journal-title":"Aust. J. Ophthalmol."},{"key":"67395_CR4","doi-asserted-by":"crossref","unstructured":"Argon laser scatter photocoagulation for prevention of neovascularization and vitreous hemorrhage in branch vein occlusion. A randomized clinical trial. Branch Vein Occlusion Study Group. Arch. Ophthalmol. 104, 34\u201341 (1986).","DOI":"10.1001\/archopht.1986.01050130044017"},{"key":"67395_CR5","doi-asserted-by":"crossref","unstructured":"Argon laser photocoagulation for macular edema in branch vein occlusion. The Branch Vein Occlusion Study Group. Am. J. Ophthalmol. 98, 271\u2013282 (1984).","DOI":"10.1016\/0002-9394(84)90316-7"},{"key":"67395_CR6","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1001\/archophthalmol.2009.234","volume":"127","author":"MS Ip","year":"2009","unstructured":"Ip, M. S. et al. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. Arch. Ophthalmol. 127, 1101\u20131114 (2009).","journal-title":"Arch. Ophthalmol."},{"key":"67395_CR7","doi-asserted-by":"publisher","first-page":"439","DOI":"10.2147\/OPTH.S75659","volume":"9","author":"S Sato","year":"2015","unstructured":"Sato, S. et al. Outcomes of microincision vitrectomy surgery with internal limiting membrane peeling for macular edema secondary to branch retinal vein occlusion. Clin. Ophthalmol. 9, 439\u2013444 (2015).","journal-title":"Clin. Ophthalmol."},{"key":"67395_CR8","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1007\/s00417-015-3219-4","volume":"254","author":"D C\u0103lug\u0103ru","year":"2016","unstructured":"C\u0103lug\u0103ru, D. & C\u0103lug\u0103ru, M. Bevacizumab treatment of macular edema in CRVO and BRVO: long-term follow-up (BERVOLT study: bevacizumab for RVO long-term follow-up). Graefes Arch. Clin. Exp. Ophthalmol. 254, 1023\u20131024 (2016).","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"67395_CR9","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1177\/0300060518819613","volume":"47","author":"Y Tao","year":"2019","unstructured":"Tao, Y. et al. Short-term effect of intravitreal conbercept injection on major and macular branch retinal vein occlusion. J. Int. Med. Res. 47, 1202\u20131209 (2019).","journal-title":"J. Int. Med. Res."},{"key":"67395_CR10","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1002\/0471142727.mb1415s102","volume":"102","author":"SM Hartig","year":"2013","unstructured":"Hartig, S. M. Basic image analysis and manipulation in ImageJ. Curr. Protoc. Mol. Biol. 102, 11\u201312 (2013).","journal-title":"Curr. Protoc. Mol. Biol."},{"key":"67395_CR11","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/nmeth.2089","volume":"9","author":"CA Schneider","year":"2012","unstructured":"Schneider, C. A., Rasband, W. S. & Eliceiri, K. W. NIH Image to ImageJ: 25 years of image analysis. Nat. methods 9, 671\u2013675. https:\/\/doi.org\/10.1038\/nmeth.2089 (2012).","journal-title":"Nat. methods"},{"key":"67395_CR12","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/S0002-9394(14)74791-9","volume":"113","author":"RM Feist","year":"1992","unstructured":"Feist, R. M., Ticho, B. H., Shapiro, M. J. & Farber, M. Branch retinal vein occlusion and quadratic variation in arteriovenous crossings. Am. J. Ophthalmol. 113, 664\u2013668 (1992).","journal-title":"Am. J. Ophthalmol."},{"key":"67395_CR13","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/S0161-6420(80)35271-8","volume":"87","author":"L Joffe","year":"1980","unstructured":"Joffe, L., Goldberg, R. E., Magargal, L. E. & Annesley, W. H. Macular branch vein occlusion. Ophthalmology 87, 91\u201398 (1980).","journal-title":"Ophthalmology"},{"issue":"101","key":"67395_CR14","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1152\/japplphysiol.00448.2006","volume":"1985","author":"CN Young","year":"2006","unstructured":"Young, C. N., Stillabower, M. E., DiSabatino, A. & Farquhar, W. B. Venous smooth muscle tone and responsiveness in older adults. J. Appl. Physiol. 1985(101), 1362\u20131367 (2006).","journal-title":"J. Appl. Physiol."},{"key":"67395_CR15","first-page":"1534","volume":"11","author":"AH Bayat","year":"2018","unstructured":"Bayat, A. H. et al. Comparison of one and three initial monthly intravitreal ranibizumab injection in patients with macular edema secondary to branch retinal vein occlusion. Int. J. Ophthalmol. 11, 1534\u20131538 (2018).","journal-title":"Int. J. Ophthalmol."},{"key":"67395_CR16","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1097\/IAE.0b013e318030e77e","volume":"27","author":"MD Rabena","year":"2007","unstructured":"Rabena, M. D., Pieramici, D. J., Castellarin, A. A., Nasir, M. A. & Avery, R. L. Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to branch retinal vein occlusion. Retina 27, 419\u2013425 (2007).","journal-title":"Retina"},{"key":"67395_CR17","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1097\/ICU.0b013e3282fb7fb0","volume":"19","author":"F Badala","year":"2008","unstructured":"Badala, F. The treatment of branch retinal vein occlusion with bevacizumab. Curr. Opin. Ophthalmol. 19, 234\u2013238 (2008).","journal-title":"Curr. Opin. Ophthalmol."},{"key":"67395_CR18","doi-asserted-by":"publisher","first-page":"396","DOI":"10.4103\/0301-4738.116461","volume":"62","author":"RI Ali","year":"2014","unstructured":"Ali, R. I., Kapoor, K. G., Khan, A. N. & Gibran, S. K. Efficacy of combined intravitreal bevacizumab and triamcinolone for branch retinal vein occlusion. Indian J. Ophthalmol. 62, 396\u2013399 (2014).","journal-title":"Indian J. Ophthalmol."},{"key":"67395_CR19","doi-asserted-by":"publisher","first-page":"94","DOI":"10.4103\/0974-620X.53042","volume":"2","author":"S Deka","year":"2009","unstructured":"Deka, S., Kalita, K. & Singh, S. K. Rebound effect following intravitreal bevacizumab in branch retinal vein occlusion. Oman J. Ophthalmol. 2, 94\u201395 (2009).","journal-title":"Oman J. Ophthalmol."},{"key":"67395_CR20","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/s0002-9394(14)70001-7","volume":"117","author":"SS Hayreh","year":"1994","unstructured":"Hayreh, S. S., Zimmerman, M. B. & Podhajsky, P. Incidence of various types of retinal vein occlusion and their recurrence and demographic characteristics. Am. J. Ophthalmol. 117, 429\u2013441. https:\/\/doi.org\/10.1016\/s0002-9394(14)70001-7 (1994).","journal-title":"Am. J. Ophthalmol."},{"key":"67395_CR21","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1038\/eye.2000.230","volume":"14","author":"MD Tsaloumas","year":"2000","unstructured":"Tsaloumas, M. D. et al. Nine year follow-up study of morbidity and mortality in retinal vein occlusion. Eye (London, England) 14, 821\u2013827. https:\/\/doi.org\/10.1038\/eye.2000.230 (2000).","journal-title":"Eye (London, England)"},{"key":"67395_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.preteyeres.2014.04.001","volume":"41","author":"SS Hayreh","year":"2014","unstructured":"Hayreh, S. S. Ocular vascular occlusive disorders: natural history of visual outcome. Prog. Retin. Eye. Res. 41, 1\u201325. https:\/\/doi.org\/10.1016\/j.preteyeres.2014.04.001 (2014).","journal-title":"Prog. Retin. Eye. Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-67395-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-67395-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-67395-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T12:26:04Z","timestamp":1670329564000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-67395-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,24]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["67395"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-67395-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,24]]},"assertion":[{"value":"1 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10272"}}